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1) Dipartimento di Medicina Interna e Specialità Mediche, Sapienza Università di Roma and 2) Istituto Pasteur-Fondazione Cenci Bolognetti, Rome, ItalyAbstractHepatitis B virus (HBV) or hepatitis C virus (HCV) infections represent major causes of chronic liver disease and hepatocellular carcinoma.
Despite inducing shared pathological events leading to oncogenic transformation, these two viruses present profound differences in their
molecular features, life cycle and interplay with host factors, which signiﬁcantly differentiate the prognostic and therapeutic approach to
the related diseases. In the present review, we report the main mechanisms involved in the multistep process leading from HCV/HBV
infection and cancer development, discussing side-by-side the analogies and differences between the two viruses. Such events can be
broadly categorized into (a) direct oncogenic effects, involving integration in the host genome (in the case of HBV) and chromosomal
instability, interference with oncosuppressor pathways, induction of oxidative stress, promotion of angiogenesis, epithelial–mesenchymal
transition, alterations in the epigenetic asset and interaction with non-coding RNAs; and (b) indirect activities mostly mediated by host
events, including chronic inﬂammation sustained by peculiar cytokine networks (such as interleukin-6 and lymphotoxins), metabolic
dysfunctions promoted by steatohepatitis, interplay with gut microbiota and ﬁbrotic events (mainly in HCV infection). This scenario
suggests that the integrated study of viral and host factors may lead to the successful development of novel biomarkers and targets for
therapy.
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hepatitis C virusesHepatitis B virus (HBV) and hepatitis C virus (HCV) are major
aetiological agents of chronic liver disease and hepatocellular
carcinoma (HCC). HCC is the ﬁfth most prevalent tumour type
and the third leading cause of cancer-related deaths worldwide.
In Africa and Asia, where HBV is endemic, 60% of HCC is
associated with HBV, 20% is related to HCV; in the USA,
Europe, Egypt and Japan, more than 60% of HCC is associated
with HCV, about 20% is related to HBV [1].Clinical Microbiology and Infection © 2015 European Society of CHepatitis B virus is a hepadnavirus that replicates via an RNA
intermediate. The HBV genome is a partially double-stranded
relaxed circular DNA molecule of 3.2 kb; when HBV enters
hepatocytes the relaxed circular DNA is converted into a
covalently closed circular DNA. This covalently closed circular
DNA is organized as a mini-chromosome by histone and non-
histone viral and cellular proteins [2] and serves as template
for transcription of all viral mRNAs. It persists during therapy
using nucleos(t)ide analogues that suppress HBV replication,
therefore disease recurrence is possible even after successful
treatment and clearance of hepatitis B surface antigen [3]. HBV
can promote HCC in many ways, including through its integra-
tion in the host genome. HBV–DNA integration into human
chromosomes has been detected in 80–90% of HBV-related
HCCs and insertions have been associated with genetic alter-
ations within the cell genome, including generalized genomic
instability, gene and chromosomal deletions, translocations,
ampliﬁcations of cellular DNA, and generation of fusionClin Microbiol Infect 2015; 21: 969–974
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proaches have identiﬁed recurrent sites for HBV–DNA inte-
gration [5]. Genes reported to be frequently altered are TERT,
MLL4, CCNE1, NTRK2, IRAK2 and MAPK1 [6]. The risk of HCC
development may remain elevated also in individuals that are
negative for circulating HBsAg even if the virus persists in the
liver: this condition is known as occult HBV infection (OBI)
[7–9]. Several studies indicate that OBI represents an important
risk factor for HCC development because long-term persistence
of occult HBV may exert both an indirect role, supporting a mild
necroinﬂammation, and a direct oncogenic effect, mediated by its
integration into the host genome, as well as by maintaining the
expression of transforming proteins like X-protein [10,11].
Moreover, consistent epidemiological studies have shown that
OBI is associated with a more severe liver disease in HCV-
infected patients, suggesting that OBI may synergize with HCV-
mediated hepatitis in co-infected subjects [12–14].
Hepatitis C virus is an enveloped virus with positive-sense
RNA genome of 9.6 kb that encodes for structural (Core, E1,
E2/p7) and non-structural (NS2, NS3, NS4A, NS4B, NS5A and
NS5B) proteins. It is a virus with an exclusively cytoplasmic life
cycle, and maintains itself as an endoplasmic reticulum-
associated episome. The mechanisms of HCV-induced HCC
involve the interplay of host, environmental and viral factors.
Unlike HBV, HCV does not integrate into the host genome but,
like HBV, can induce chromosomal instability by direct effects
of its proteins on genes that regulate organization of cen-
trosomal processes and the mitotic spindle during cell cycle
progression [15].
Both host and viral factors have been recognized to impact
HCC development/progression in HBV and/or HCV-infected
individuals. Several host and environmental components,
including metabolic syndrome, tobacco or alcohol intake, and
genetic factors, contribute to determine HCC risk in both HCV
and HBV infections. Conversely, viral factors seem to differ-
entially affect HCC development in the two infections: indeed,
although cirrhosis plays a major role in HCV-related carcino-
genesis, viral factors represent strong prognostic indicators of
HCC development in HBV infection, also in the absence of
cirrhosis [1]. They include high levels of viral replication [16],
the viral genotype (with the B genotype found prevalent in
cohort of HCC carriers [17]), and the presence of speciﬁc
point mutations in the basal core protein promoter [18,19] or
deletions in pre-S sequence [20]. This scenario clearly antici-
pates the idea that the two viruses, and respectively HBV or
HCV, may preferentially rely on direct virus-related oncogenic
activities rather than on indirect inﬂammatory and ﬁbrotic
events, when arranging liver carcinogenesis.
Both HBV and HCV contribute to HCC induction by directly
promoting host gene expression pathways and cellularClinical Microbiology and Infection © 2015 European Society of Clinical Microbiology and Infectphenotypes that have been recognized as hallmarks of cancer,
i.e. growth factor-independent proliferation, resistance to
growth inhibition, tissue invasion and metastasis, angiogenesis,
reprogramming of energy metabolism, resistance to apoptosis,
and induction of oxidative stress [21]. The contribution of HBV
to HCC involves the expression of hepatitis B x (HBx) and pre-
S or S polypeptides, while the HCV core protein and non-
structural proteins NS3 and NS5A contribute to oncogenic
processes. Indeed, HBx, HCV core and NS5A were reported to
interact with wild-type p53 and limit its functions [22], including
nucleotide excision repair and transcription-coupled repair
[23]. Oxidative stress is induced by both HBV and HCV by
altering Ca2+ signalling and increasing reactive oxygen species
levels that in turn trigger endoplasmic reticulum stress [24,25].
However, endoplasmic reticulum integrity is important for vi-
rus replication, therefore both viruses trigger the unfolded
protein response and autophagy to restore endoplasmic retic-
ulum functions [26,27].
Hypervascularization is a major characteristic of HCC. HBV
and HCV (HBx, HCV Core, E1, NS3, NS5A) promote angio-
genesis by upregulating hypoxia inducible factor 1α [28–30]
that orchestrates the response to hypoxia by transcriptionally
upregulating vascular endothelial growth factor and cyclo-
oxygenase 2, and by activating matrix metalloproteinases [30].
On the basis of this evidence, anti-angiogenic treatments have
been proposed in HCC, such as Sorafenib that is the ﬁrst
molecular target drug approved for the treatment of advanced
HCC. However, the efﬁcacy and safety of anti-angiogenic
therapies remain controversial and substantial evidence of pri-
mary and acquired resistance to Sorafenib has been reported
[31].
Hepatocellular carcinoma is a complex and heterogeneous
tumour with frequent intrahepatic spread and extrahepatic
metastasis. Liver ﬁbrogenesis, tumour progression and metas-
tasis are induced by epithelial–mesenchymal transition, which
occurs in response to sustained inﬂammation, ultimately leading
to organ destruction. Both HBV and HCV promote epithe-
lial–mesenchymal transition by induction of transforming
growth factor-β1 and SNAIL and by activation of RAS-ERK,
phosphoinositide 3-kinase (PI3K)-AKT and Wingless-type
MMTV integration site family (Wnt) signalling pathways
[32–34]. In human HCC, mutations in Wnt/β-catenin signalling
are common (15–33% CTNNB1, 15% AXIN1 and 1–2% APC)
[35]. HBx can activate β-catenin by upregulation of Upregulated
gene clone 11 (URG11), inactivation of E-cadherin complexes,
upregulation of SNAIL and activation of the proto-oncogene
Src [21], while NS5A can trigger β-catenin activation by upre-
gulating Twist family BHLH transcription factor 2 (TWIST2)
[32] and by activating PI3K-AKT [36]. Stabilization of β-catenin
promotes the transcription of stemness-related genes (e.g.ious Diseases. Published by Elsevier Ltd. All rights reserved, CMI, 21, 969–974
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adhesion molecule, which in turn contributes to the stemness
of cancer cells through binding to target genes [37]. Moreover,
β-catenin can enhance the transcription of hypoxia inducible
factor 1α, therefore promoting cell survival and epithelial–
mesenchymal transition, favouring the stemness of cancer cells
and overcoming hypoxia [38,39].
Epigenetic changes are known to contribute to HBV-induced
and HCV-induced HCC. Epigenetic modiﬁcations of tumour
suppressor genes may permit the constitutive expression of
oncogenes that is characteristic of tumour progression. The
heritable epigenetic changes acquired, along with tumour
expansion, result in a permanent phenotypical change. Both
viruses upregulate DNA methyltransferases [40,41], and indeed
DNA hypermethylation in the promoter region of speciﬁc
oncosuppressor genes was found in HBV- and HCV-related
HCC [42]. For example, HCV core protein and HBx sup-
press the cyclin-dependent kinase inhibitors INK4a and p21
through promoter methylation, an event that in turn de-
termines the inactivation of the Retinoblastoma tumour sup-
pressor [21]. Moreover, both HBx and HCV core induce DNA
methylation in the E-cadherin promoter [42], ultimately acti-
vating β-catenin.
HBV and HCV can alter the expression of selected mito-
chondrial RNAs and long non-coding RNAs that affect virus
persistence and oncogene/oncosuppressor pathways in HCC
[43,44]. For instance, miR122 has been shown to be an essential
host factor for HCV infection and an antiviral target because it
stimulates virus replication by stabilizing the viral RNA in
infected cells [45]. A recent work has proposed a model for
HCV-induced miR-122 sequestration that may result in global
de-repression of host miR-122 targets, providing a fertile
environment for the long-term oncogenic potential of HCV
[46]. HBV infection downregulates the expression of miR122,
which interferes with viral replication, and viral load inversely
correlates with miR122 expression in HBV-infected patients
[47]. Given its central role in liver biology, miR122 represents
an interesting therapeutic target for the treatment of liver
diseases and HCC [45]. Given the role of deregulated miRNAs
in host–virus interaction and HCC development, these mole-
cules have the potential to become novel diagnostic and
prognostic biomarkers and therapeutic targets in virus-related
diseases.
Current treatments of hepatitis B comprise pegylated
interferon-α and oral nucleoside/nucleotide analogues, which
often lead to viral suppression, decrease the risk of HCC as
well as post-surgery HCC recurrence but rarely lead to com-
plete virus eradication [48]. A highly efﬁcacious vaccine has
been developed for HBV, but the implementation of vaccination
programmes is not uniform, and vaccine non-responders andClinical Microbiology and Infection © 2015 European Society of Clinical Microbiologyvaccine-escape mutants have limited the effectiveness of the
vaccine [49,50]. Prevention strategies, large data sets from
next-generation sequencing analysis of HBV–DNA integration
sites, eradication of the covalently closed circular DNA mole-
cule as well as identiﬁcation of new biomarkers represent the
main goal for the treatment of HBV-induced HCC. For HCV,
with the development of new direct-acting antiviral agents,
sustained virological response rates have risen to >90%. The US
Food and Drug Administration approved Sofosbuvir for the
treatment of patients with HCV genotypes 1, 2, 3 and 4;
however, further genetic and functional studies are needed to
identify novel biomarkers and prevention strategies in HCV-
associated cancer.HBV/HCV-driven inﬂammatory response
and liver carcinogenesisThe tight link between chronic inﬂammation and tumour initi-
ation/promotion has been established from a huge amount of
data [51,52]. Cells of both innate and adaptive arms of the
immune response are recruited and/or locally expanded in
tissues in response to injuries of different origin (chemical
damage, metabolic pressure, infectious trigger, or other) and
arrange a series of activities, originally directed to the
neutralization of the instigating factor and to efﬁcient tissue
repair, but later turning into deleterious chronic low-grade
inﬂammation and regenerative mechanisms, fostering onco-
genic transformation [51,52]. Several pieces of evidence indi-
cate that HBV and HCV infections promote hepatocellular
carcinogenesis not only directly, through the direct oncogenic
activities of speciﬁc viral proteins, but also indirectly, by
establishing chronic low-grade inﬂammation and ﬁbrosis.
Pioneer studies in mouse models have clearly demonstrated
that the transgenic expression of HBV proteins was not sufﬁ-
cient per se to recapitulate the HBV-related liver disease, and
that the HBV-speciﬁc T-cell response was required to initiate in
HBV-transgenic mice a process of chronic hepatitis, sustained
by non-HBV-speciﬁc T cells and other players such as neutro-
phils, macrophages and natural killer cells, ﬁnally leading to
HCC development [53,54]. Similarly, a very low incidence of
HCC has been reported in several lines of HCV-transgenic
mice, spontaneously developing steatosis in the absence of
overt inﬂammation [55]; again supporting the idea that chronic
inﬂammation crucially determines the oncogenic power of
HCV infection. Many diverse immunological mechanisms,
instigated by HBV/HCV infections, may participate in HCC
promotion [52]. Hepatic levels of the cytokines lymphotoxins α
and β were speciﬁcally increased in human HBV-related andand Infectious Diseases. Published by Elsevier Ltd. All rights reserved, CMI, 21, 969–974
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mice that highly express lymphotoxins speciﬁcally in the liver
displayed strong inﬂammatory inﬁltration, hepatocellular dam-
age and spontaneous HCC development [56]. Lymphotoxins
mainly acted by triggering the hepatocyte-intrinsic IKKβ-
dependent nuclear factor-κB pathway, which in turn promoted
chemokine release and recruitment of inﬂammatory cells
responsible for hepatic remodelling and HCC development
[56]. HCV infection was directly able to induce lymphotoxin
expression in a human hepatocyte cell line, even though im-
mune cells also contributed to lymphotoxin provision [56]. In
particular, NS5B, the RNA-dependent RNA polymerase of
HCV, was directly able to induce lymphotoxin expression in
hepatocytes [57]. Similarly, other HCV viral proteins can
directly induce pro-inﬂammatory signalling pathways leading to
nuclear factor-κB activation and to the release of pro-
tumorigenic cytokines [58,59]. While lymphotoxins may exert
more relevant functions at early phases of virus-related
inﬂammation, other cytokines and chemokines may rather
contribute to amplify the immune-hepatocyte cross-talk at later
stages. In a mouse model of chemical hepatocarcinogenesis,
interleukin-6 (IL-6) was found to be responsible for the gender
disparity in HCC development, through the repressive effect of
oestrogens on IL-6 secretion by Kupffer cells [60], and high
levels of serum IL-6 predicted HCC induction in chronic HBV
[61] and HCV [62] infections. Many other cytokines, such as
tumour necrosis factor, IL-1 and IL-23, produced in conditions
of chronic inﬂammation, may contribute to tumour initiation/
promotion, through converging to the activation of pro-
tumorigenic NF-κB and signal transducer and activator of
transcription 3 pathways [52].
The HBV/HCV-related chronic inﬂammation may lead to
oncogenic transformation not only through the direct instiga-
tion of transforming events but also indirectly, through meta-
bolic alterations occurring in steatohepatitis and through the
tissue remodelling processes that are associated with hepatic
cirrhosis. However, such indirect events may have a higher
impact in HCV than in HBV infections. Indeed, the risk of HCC
development is related to the extent of viral replication and
virus-directed immunity in the case of HBV infection, while
being more closely associated with host factors such as meta-
bolic dysfunctions and ﬁbrotic processes in the case of HCV
infection [63]. Both viruses contain steatogenic proteins that
reshape hepatic lipid metabolism and induce hepatic steatosis,
which contributes to the induction of oncogenic pathways in a
hepatocyte-intrinsic fashion [64]. However, virus-driven stea-
tosis may also contribute to carcinogenesis extrinsically,
through the establishment of hepatic and/or systemic metabolic
inﬂammation that plays pro-tumorigenic roles. Indeed, chemical
liver carcinogenesis is strongly enhanced by dietary or geneticClinical Microbiology and Infection © 2015 European Society of Clinical Microbiology and Infectcaloric overload [65] and obesity increases the HCC risk [63].
Importantly, obesity and diabetes synergize with HCV infection,
more than with HBV infection, in determining HCC risk [66]. In
a mouse model of combined steatohepatitis and obesity, CD8 T
cells and NKT cells were found to be responsible not only for
inﬂammation and HCC development but also for triggering lipid
metabolism alterations in hepatocytes [67]. This scenario is
complicated by recent observations indicating that obesity may
affect cancer risk not only through metabolic or inﬂammatory
dysfunctions but also through the involvement of a guilty
bystander, which is the gut microbiota. Exposure to Helicobacter
hepaticus signiﬁcantly enhances HCC development in HCV-
transgenic mice [68] and dietary overload reshufﬂes the gut
microbial colonization leading to the release of bacterial me-
tabolites that in turn promote HCC development [69].
A relevant difference between HBV-related and HCV-related
HCC is the impact of cirrhosis, more strictly associated to
HCC in the case of chronic HCV infection [63,70]. HCV viral
proteins directly induce, in hepatic stellate cells, the release of
proﬁbrogenic mediators and also of inﬂammatory cytokines and
chemokines that further amplify cycles of tissue damage/repair
[71]. The cytokine transforming growth factor-β may be
considered as a critical cytokine bridging cirrhosis and carci-
nogenesis [72]. Interestingly, transforming growth factor-β
plays a variety of immunosuppressive activities, therefore
turning cirrhosis into a tolerant microenvironment that may
favour the escape of emerging tumour clones from immune
control. In line with this idea, our recent data have underscored
the accumulation of regulatory T cells, crucial suppressors of
anti-tumour immune responses, not only in HCC but also in
cirrhosis of HCV-infected patients, indicating that immuno-
suppression may represent an early event in the multistep
process leading from HCV-related cirrhosis to cancer [73]. The
study of host-related factors/networks contributing to the
oncogenic evolution of HCV/HBV-induced chronic liver dis-
eases may lead to the discovery of novel biomarkers for pre-
dicting disease progression and, importantly, of potential targets
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